Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

January 31, 2014 updated by: Boehringer Ingelheim

A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects

The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

997

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Capital Federal, Argentina
        • 1182.17.5401 Fundacion Huesped
      • Capital Federal, Argentina
        • 1182.17.5402 Funcei
      • Capital Federal, Argentina
        • 1182.17.5403 consultorio externo "PETS"
      • Capital Federal, Argentina
        • 1182.17.5404 Infectología
      • Capital Federal, Argentina
        • 1182.17.5405 Dpto. de Enfermedades infecciosas (Pabellón 22)
      • Capital Federal, Argentina
        • 1182.17.5406 Pabellón de Clínicas 2° Piso
  • Australia
    • New South Wales
      • DarlingHurst, New South Wales, Australia
        • 1182.17.405 AIDS Research Initiative
      • Darlinghurst, New South Wales, Australia
        • 1182.17.401 St. Vincent's Hospital
      • Darlinghurst, New South Wales, Australia
        • 1182.17.402 Taylor Square Private Clinic
      • Darlinghurst, New South Wales, Australia
        • 1182.17.407 Holdsworth House General Practice
      • Darlinghurst, New South Wales, Australia
        • 1182.17.408 407 Doctors Pty Ltd.
      • Surry Hills, New South Wales, Australia
        • 1182.17.403 Albion Street Clinic
    • Victoria
      • Melbourne, Victoria, Australia
        • 1182.17.404 Alfred Hospital
  • Austria
      • Wien, Austria
        • 1182.17.4301 Boehringer Ingelheim Investigational Site
  • Belgium
      • Antwerpen, Belgium
        • 1182.17.3209 Instituut Tropische Geneeskunde
      • Bruxelles, Belgium
        • 1182.17.3201 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgium
        • 1182.17.3202 Boehringer Ingelheim Investigational Site
      • Gent, Belgium
        • 1182.17.3207 Boehringer Ingelheim Investigational Site
      • Luxembourg, Belgium
        • 1182.17.3210 Centre Hospitalier de Luxembourg
  • Brazil
      • Canela - Salvador - BA, Brazil
        • 1182.17.5511 Universidade Federal da Bahia
      • Cerqueira César, São Paulo - SP, Brazil
        • 1182.17.5508 I.I. Emilio Ribas
      • Cidade Nova - Rio de Janeiro - RJ, Brazil
        • 1182.17.5509 (Unidade de Testes Terapêuticos)
      • Manguinhos - Rio de Janeiro - RJ, Brazil
        • 1182.17.5502 Farmácia do Instituto de Pesquisa Evandro Chagas
      • Mercês - Curitiba - PR, Brazil
        • 1182.17.5505 Instituto A-Z de Pesquisa e Ensino da PUC
      • Nova Iguaçu - Rio de Janeiro - RJ, Brazil
        • 1182.17.5507 Hospital Geral de Nova Iguaçu - Ministério da Saúde
      • Sacoma - São Paulo - SP, Brazil
        • 1182.17.5501 Hospital Dia
      • São Paulo - SP, Brazil
        • 1182.17.5503 Instituto de Infectologia Emílio Ribas
      • São Paulo - SP, Brazil
        • 1182.17.5504 Enfermaria de MI
      • São Paulo, SP, Brazil
        • 1182.17.5510 Casa de AIDS
      • Vila Mariana, Sao Paulo - SP, Brazil
        • 1182.17.5506 Centro de Referência e Treinamento - DST/AIDS
  • Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
        • 1182.17.902 Downtown Infectious Diseases Clinic
    • Ontario
      • Hamilton, Ontario, Canada
        • 1182.17.913 McMaster University Medical Centre
      • Ottawa, Ontario, Canada
        • 1182.17.901 Division of Infectious Diseases
      • Toronto, Ontario, Canada
        • 1182.17.905 Canadian Immunodeficiency Research Collaborative Inc.
      • Toronto, Ontario, Canada
        • 1182.17.906 Infectious Diseases & HIV - St. Michael's Hospital
      • Toronto, Ontario, Canada
        • 1182.17.907 University Health Network - Toronto General Hospital
      • Toronto, Ontario, Canada
        • 1182.17.910 Sunnybrook & Women's College Health Science Centre
    • Quebec
      • Monteal, Quebec, Canada
        • 1182.17.914 Montreal General Hospital - McGill University Health Centre
      • Montreal, Quebec, Canada
        • 1182.17.903 Montreal Chest Institute, McGill University Health Centre
      • Montreal, Quebec, Canada
        • 1182.17.904 Clinique Medicale Du Quartier Latin
      • Montreal, Quebec, Canada
        • 1182.17.915 Clinique medicale l'Actuel
  • Denmark
      • Aarhus N, Denmark
        • 1182.17.4505 Boehringer Ingelheim Investigational Site
      • Copenhagen Ø, Denmark
        • 1182.17.4501 Boehringer Ingelheim Investigational Site
      • Hvidovre, Denmark
        • 1182.17.4502 Boehringer Ingelheim Investigational Site
      • Odense, Denmark
        • 1182.17.4504 Boehringer Ingelheim Investigational Site
  • France
      • Bordeaux cedex, France
        • 1182.17.33011 Hôpital Pellegrin
      • Bordeaux cedex, France
        • 1182.17.33019 Hôpital Saint André
      • Caen cedex 5, France
        • 1182.17.33020 Hôpital Côte de Nacre
      • Clamart, France
        • 1182.17.33007 Hôpital Antoine Beclere
      • Lyon cedex 2, France
        • 1182.17.33008 Hôpital de l'Hôtel Dieu
      • Lyon cedex 3, France
        • 1182.17.33023 Hôpital Edouard Herriot
      • Marseille cedex 5, France
        • 1182.17.33012 Hôpital de la Conception
      • Marseille cedex 9, France
        • 1182.17.33013 Hôpital Sainte Marguerite
      • Nantes cedex 1, France
        • 1182.17.00336 Hôpital Hôtel Dieu
      • Nice cedex 3, France
        • 1182.17.33010 Hôpital de l'Archet
      • Paris, France
        • 1182.17.00333 Hôpital Saint Louis
      • Paris, France
        • 1182.17.00334 Hôpital de la Pitié Salpêtrière
      • Paris, France
        • 1182.17.33014 Hôpital Saint Antoine
      • Paris cedex 14, France
        • 1182.17.33024 Groupe Hospitalier Cochin
      • Paris cedex 15, France
        • 1182.17.33022 Hôpital Européen Georges Pompidou
      • Paris cedex 18, France
        • 1182.17.00335 Hôpital Bichat Claude Bernard
      • Paris cedex 20, France
        • 1182.17.00331 Hôpital Tenon
      • Rennes cedex 9, France
        • 1182.17.33018 Hôpital de Pontchaillou
      • Strasbourg cedex, France
        • 1182.17.33016 Hôpital Civil
      • Toulon, France
        • 1182.17.00332 Hôpital du Chalucet
      • Vandoeuvre les Nancy, France
        • 1182.17.33017 Hôpital Brabois Adultes
      • Villejuif cedex, France
        • 1182.17.33021 Hôpital Paul Brousse
  • Germany
      • Aachen, Germany
        • 1182.17.4911 Arzt für Innere Medizin
      • Berlin, Germany
        • 1182.17.4901 Epimed GmbH c/o
      • Berlin, Germany
        • 1182.17.4902 Charite, Campus Virchow-Klinikum
      • Bonn, Germany
        • 1182.17.4918 Rheinische Friedrich-Wilhelm-Universität
      • Dortmund, Germany
        • 1182.17.4906 ID-Ambulanz Klinikum Dortmund
      • Düsseldorf, Germany
        • 1182.17.4912 Universitätsklinikum Düsseldorf
      • Düsseldorf, Germany
        • 1182.17.4914 Arzt für Innere Medizin
      • Erlangen, Germany
        • 1182.17.4908 Universitätskliniken Erlangen
      • Essen, Germany
        • 1182.17.4904 Universitätsklinikum Essen
      • Frankfurt/Main, Germany
        • 1182.17.4924 Klinikum der J. W.-Goethe-Universität
      • Freiburg, Germany
        • 1182.17.4928 Facharzt für Innere Medizin/Rheumatologie
      • Freiburg/Breisgau, Germany
        • 1182.17.4930 Universitätsklinikum Freiburg
      • Hamburg, Germany
        • 1182.17.4916 Medizinisches Versorgungszentrum Hamburg
      • Hamburg, Germany
        • 1182.17.4929 Universitätsklinikum Eppendorf
      • Hamburg, Germany
        • 1182.17.4931 IPM Study Center GmbH
      • Hannover, Germany
        • 1182.17.4920 Abteilung Klinische Immunologie
      • Heidelberg, Germany
        • 1182.17.4909 Universitätsklinikum Heidelberg
      • Köln, Germany
        • 1182.17.4905 Universitätsklinik Köln
      • Köln, Germany
        • 1182.17.4926 Internist
      • Mannheim, Germany
        • 1182.17.4923 Facharzt für Innere Medizin,
      • München, Germany
        • 1182.17.4907 Medizinische Poliklinik
      • München, Germany
        • 1182.17.4910 MUC Research GmbH
      • Osnabrück, Germany
        • 1182.17.4915 Klinium Natruper Holz
      • Stuttgart, Germany
        • 1182.17.4921 Arzt für Allgemeinmedizin
  • Greece
      • Athens, Greece
        • 1182.17.3001 Boehringer Ingelheim Investigational Site
      • Athens, Greece
        • 1182.17.3002 Boehringer Ingelheim Investigational Site
      • Athens, Greece
        • 1182.17.3003 Boehringer Ingelheim Investigational Site
      • Athens, Greece
        • 1182.17.3004 Boehringer Ingelheim Investigational Site
      • Athens, Greece
        • 1182.17.3007 Boehringer Ingelheim Investigational Site
      • Patras, Greece
        • 1182.17.3010 Boehringer Ingelheim Investigational Site
      • Thessaloniki, Greece
        • 1182.17.3009 Boehringer Ingelheim Investigational Site
  • Italy
      • Antella (fi), Italy
        • 1182.17.0409 Ospedale Santa Maria Annunziata
      • Busto Arsizio (va), Italy
        • 1182.17.0413 Ospedale di Circolo di Busto
      • Ferrara, Italy
        • 1182.17.0384 Azienda Ospedaliera Arcispedale S. Anna
      • Genova, Italy
        • 1182.17.0397 Ospedale San Martino
      • Genova, Italy
        • 1182.17.0412 S.C. Malattie Infettive
      • Lecco, Italy
        • 1182.17.0411 Presidio Ospedaliero "A. Manzoni"
      • Macerata, Italy
        • 1182.17.0389 Reparto Malattie Infettive
      • Milano, Italy
        • 1182.17.0393 Fondazione Centro S. Raffaele del Monte Tabor
      • Modena, Italy
        • 1182.17.0386 Policlinico Universitario
      • Napoli, Italy
        • 1182.17.0388 Ospedale A. Cotugno
      • Pavia, Italy
        • 1182.17.0385 IRCCS Policlinico San Matteo
      • Pavia, Italy
        • 1182.17.0394 IRCCS Policlinico San Matteo
      • Roma, Italy
        • 1182.17.0395 Azienda Policlinico Umberto I
      • Roma, Italy
        • 1182.17.0419 I Cattedra Malattie Infettive
      • Torino, Italy
        • 1182.17.0387 Ospedale Amedeo di Savoia
      • Torino, Italy
        • 1182.17.0398 Ospedale Amedeo di Savoia
      • Torino, Italy
        • 1182.17.0415 U.O.A. Malattie Infettive B
  • Mexico
      • Col. La Raza, Mexico, Mexico
        • 1182.17.5201 Centro Médico La Raza IMSS
      • Guadalajara, Mexico
        • 1182.17.5203 Hospital Civil Nuevo de Guadalajara
      • Monterrey, N.l., Mexico, Mexico
        • 1182.17.5206 Centro Medico San Vicente
  • Netherlands
      • Amsterdam, Netherlands
        • 1182.17.3101 Boehringer Ingelheim Investigational Site
      • Groningen, Netherlands
        • 1182.17.3108 Boehringer Ingelheim Investigational Site
      • Nijmegen, Netherlands
        • 1182.17.3105 Boehringer Ingelheim Investigational Site
      • Rotterdam, Netherlands
        • 1182.17.202 Boehringer Ingelheim Investigational Site
  • Portugal
      • Cascais, Portugal
        • 1182.17.3502 Hospital Condes Castro Guimarães
  • Spain
      • Badalona, Spain
        • 1182.17.705 Hospital Germans Trias i Pujol
      • Barcelona, Spain
        • 1182.17.701 Hospital Clínico y Provincial de Barcelona
      • Madrid, Spain
        • 1182.17.703 Hospital 12 de Octubre
      • Madrid, Spain
        • 1182.17.704 Hospital Ramón y Cajal.
      • Madrid, Spain
        • 1182.17.710 Hospital Gregorio Maranon
      • Madrid, Spain
        • 1182.17.712 Hospital Clínico San Carlos
      • Malaga, Spain
        • 1182.17.717 Hospital Clínico Universitario Vírgen de la Victoria
      • Sevilla, Spain
        • 1182.17.713 Hospital Universitario Vírgen del Rocío
      • Valencia, Spain
        • 1182.17.714 Hospital General Universitario de Valencia
      • Valencia, Spain
        • 1182.17.720 Hospital La Fe
      • Vigo, Spain
        • 1182.17.718 Complejo Hospitalario Xeral - Cíes
  • Switzerland
      • Basel, Switzerland
        • 1182.17.4101 DIM / Abteilung für Infektiologie
      • Genève, Switzerland
        • 1182.17.4104 Département de médicine interne Div. Des maladies infectieus
      • St. Gallen, Switzerland
        • 1182.17.4103 DIM / Abteilung für Infektiologie
      • Zürich, Switzerland
        • 1182.17.4102 Departement für Innere Medizin
  • United Kingdom
      • Brighton, United Kingdom
        • 1182.17.4405 Boehringer Ingelheim Investigational Site
      • Liverpool, United Kingdom
        • 1182.17.4411 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4404 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4406 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4408 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4409 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4414 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1182.17.4418 Boehringer Ingelheim Investigational Site
      • Portsmouth, United Kingdom
        • 1182.17.4407
  • United States
    • Arizona
      • Phoenix, Arizona, United States
        • 1182.17.39 MDS Pharma Services
      • Phoenix, Arizona, United States
        • 1182.17.75 Boehringer Ingelheim Investigational Site
    • California
      • Berkeley, California, United States
        • 1182.17.89 Boehringer Ingelheim Investigational Site
      • Fountain Valley, California, United States
        • 1182.17.60 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • 1182.17.106 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • 1182.17.15 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • 1182.17.40 Tower ID Medical
      • Los Angeles, California, United States
        • 1182.17.46 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • 1182.17.47 University of Southern California
      • Los Angeles, California, United States
        • 1182.17.73 Boehringer Ingelheim Investigational Site
      • San Diego, California, United States
        • 1182.17.114 Boehringer Ingelheim Investigational Site
      • San Diego, California, United States
        • 1182.17.128 Boehringer Ingelheim Investigational Site
      • San Francisco, California, United States
        • 1182.17.37 Boehringer Ingelheim Investigational Site
      • San Francisco, California, United States
        • 1182.17.58 Boehringer Ingelheim Investigational Site
      • San Francisco, California, United States
        • 1182.17.96 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Norwalk, Connecticut, United States
        • 1182.17.87 Boehringer Ingelheim Investigational Site
    • District of Columbia
      • Washington, District of Columbia, United States
        • 1182.17.112 Boehringer Ingelheim Investigational Site
      • Washington, District of Columbia, United States
        • 1182.17.43 Boehringer Ingelheim Investigational Site
      • Washington, District of Columbia, United States
        • 1182.17.65 Boehringer Ingelheim Investigational Site
    • Florida
      • Fort Lauderdale, Florida, United States
        • 1182.17.126 Boehringer Ingelheim Investigational Site
      • Fort Myers, Florida, United States
        • 1182.17.8 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1182.17.131 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1182.17.22 Boehringer Ingelheim Investigational Site
      • Orlando, Florida, United States
        • 1182.17.64 Boehringer Ingelheim Investigational Site
      • Sarasota, Florida, United States
        • 1182.17.129 Boehringer Ingelheim Investigational Site
      • South Miami, Florida, United States
        • 1182.17.51 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, United States
        • 1182.17.125 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, United States
        • 1182.17.132 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, United States
        • 1182.17.76 Boehringer Ingelheim Investigational Site
      • Vero Beach, Florida, United States
        • 1182.17.52 Boehringer Ingelheim Investigational Site
    • Georgia
      • Atlanta, Georgia, United States
        • 1182.17.77 Boehringer Ingelheim Investigational Site
      • Macon, Georgia, United States
        • 1182.17.69 Boehringer Ingelheim Investigational Site
    • Illinois
      • Chicago, Illinois, United States
        • 1182.17.136 Boehringer Ingelheim Investigational Site
      • Chicago, Illinois, United States
        • 1182.17.70 Boehringer Ingelheim Investigational Site
      • Evanston, Illinois, United States
        • 1182.17.36 Boehringer Ingelheim Investigational Site
    • Indiana
      • Indianapolis, Indiana, United States
        • 1182.17.1 Boehringer Ingelheim Investigational Site
    • Kansas
      • Wichita, Kansas, United States
        • 1182.17.32 University of Kansas School of Medicine - Wichita
    • Kentucky
      • Lexington, Kentucky, United States
        • 1182.17.102 Boehringer Ingelheim Investigational Site
      • Louisville, Kentucky, United States
        • 1182.17.21 Boehringer Ingelheim Investigational Site
    • Maine
      • Portland, Maine, United States
        • 1182.17.30 Boehringer Ingelheim Investigational Site
    • Maryland
      • Baltimore, Maryland, United States
        • 1182.17.67 Boehringer Ingelheim Investigational Site
      • Bethesda, Maryland, United States
        • 1182.17.86 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Boston, Massachusetts, United States
        • 1182.17.111 Boehringer Ingelheim Investigational Site
      • Boston, Massachusetts, United States
        • 1182.17.63 Boehringer Ingelheim Investigational Site
      • Springfield, Massachusetts, United States
        • 1182.17.74 Boehringer Ingelheim Investigational Site
    • Michigan
      • Ann Arbor, Michigan, United States
        • 1182.17.4 Boehringer Ingelheim Investigational Site
      • Detroit, Michigan, United States
        • 1182.17.115 Boehringer Ingelheim Investigational Site
      • Detroit, Michigan, United States
        • 1182.17.6 Boehringer Ingelheim Investigational Site
    • Missouri
      • Kansas City, Missouri, United States
        • 1182.17.62 Boehringer Ingelheim Investigational Site
    • Nevada
      • Las Vegas, Nevada, United States
        • 1182.17.59 Boehringer Ingelheim Investigational Site
    • New Jersey
      • Camden, New Jersey, United States
        • 1182.17.118 Early Intervention Program (EIP) Clinic
      • East Orange, New Jersey, United States
        • 1182.17.93 Boehringer Ingelheim Investigational Site
      • Hackensack, New Jersey, United States
        • 1182.17.24 Hackensack University Medical Center
      • Hillsborough, New Jersey, United States
        • 1182.17.34 ID Care, Inc.
    • New Mexico
      • Santa Fe, New Mexico, United States
        • 1182.17.50 Boehringer Ingelheim Investigational Site
    • New York
      • Albany, New York, United States
        • 1182.17.79 Boehringer Ingelheim Investigational Site
      • Mount Vernon, New York, United States
        • 1182.17.103 Boehringer Ingelheim Investigational Site
      • New York, New York, United States
        • 1182.17.105 Pollari Medical Group
      • New York, New York, United States
        • 1182.17.130 Boehringer Ingelheim Investigational Site
      • New York, New York, United States
        • 1182.17.3 Division of Infectious Diseases
      • New York, New York, United States
        • 1182.17.42 Beth Israel Medical Center
      • New York, New York, United States
        • 1182.17.5 Boehringer Ingelheim Investigational Site
      • New York, New York, United States
        • 1182.17.7 Boehringer Ingelheim Investigational Site
      • New York, New York, United States
        • 1182.17.94 Boehringer Ingelheim Investigational Site
      • Rochester, New York, United States
        • 1182.17.135 Boehringer Ingelheim Investigational Site
      • Stony Brook, New York, United States
        • 1182.17.31 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Durham, North Carolina, United States
        • 1182.17.53 Boehringer Ingelheim Investigational Site
      • Huntersville, North Carolina, United States
        • 1182.17.54 Boehringer Ingelheim Investigational Site
    • Ohio
      • Akron, Ohio, United States
        • 1182.17.134 Summa Health System
      • Cincinnati, Ohio, United States
        • 1182.17.95 Boehringer Ingelheim Investigational Site
      • Columbus, Ohio, United States
        • 1182.17.26 Boehringer Ingelheim Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • 1182.17.9 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
        • 1182.17.110 Boehringer Ingelheim Investigational Site
      • Philadelphia, Pennsylvania, United States
        • 1182.17.99 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Columbia, South Carolina, United States
        • 1182.17.23 Boehringer Ingelheim Investigational Site
    • Tennessee
      • Memphis, Tennessee, United States
        • 1182.17.11 Boehringer Ingelheim Investigational Site
      • Nashville, Tennessee, United States
        • 1182.17.18 Vanderbilt AIDS Clinical Trials Center
    • Texas
      • Dallas, Texas, United States
        • 1182.17.116 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, United States
        • 1182.17.142 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, United States
        • 1182.17.16 Nelson-Tebedo Clinic
      • Houston, Texas, United States
        • 1182.17.122 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1182.17.68 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, United States
        • 1182.17.97 Boehringer Ingelheim Investigational Site
    • Virginia
      • Annandale, Virginia, United States
        • 1182.17.10 Boehringer Ingelheim Investigational Site
    • Washington
      • Tacoma, Washington, United States
        • 1182.17.92 Boehringer Ingelheim Investigational Site
    • Wisconsin
      • Milwaukee, Wisconsin, United States
        • 1182.17.100 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

INCLUSION CRITERIA

  1. Ability and willingness to give written informed consent in accordance with institutional and federal guidelines and to comply with the investigational nature of the study and the related requirements.
  2. All subjects must have successfully completed participation in a combination tipranavir/ritonavir trial or have confirmed virologic failure in the 1182.12 or 1182.48 trials and are not able to obtain TPV by prescription. Successful completion of participation is defined as conclusion of required subject-weeks on assigned dosing (trial specific) and completion of required visits.
  3. Male and female subjects 18 years and over.
  4. Presence of Human Immunodeficiency Virus 1 (HIV-1) infection as documented by any licensed Enzyme Linked immunosorbent Assay (ELISA) test kit and confirmed by Western Blot, or HIV-1 culture, or HIV-1 antigen, or plasma HIV 1 Ribonucleic Acid (RNA) or a second antibody test by a method other than ELISA at any time prior to study entry.
  5. Adherence to previous tipranavir/ritonavir dosing protocol and adherence to visit requirements of previous protocol (as assessed by principal investigator).

  6. Acceptable screening laboratory values that indicate adequate baseline organ function. Laboratory values are considered to be acceptable if the following apply:

    • Total Cholesterol ≤400 mg/dl (<Common Toxicity Criteria (CTC) Grade 2).
    • Total Triglycerides ≤750 mg/dl (<Division of AIDS (DAIDS) Grade 2).
    • Alanine aminotransferase (ALT) ≤3.0x upper limit of normal (ULN) and Aspartate aminotransferase (AST) ≤2.5x ULN (<DAIDS Grade 1).
    • Any Grade Gamma Glutamyl transpeptidase(GGT) is acceptable.
    • Any Grade creatinine kinase is acceptable as long as there is no concurrent myopathy.
    • All other laboratory test values ≤DAIDS Grade 1.

EXCLUSION CRITERIA

  1. Female subjects who are of reproductive potential who:

    • Have a positive serum beta human chorionic gonadotropin (B HCG) at Screening/Enrollment Visit.
    • Are not willing to use a reliable method of barrier contraception (such as diaphragm or condoms).
    • Are breast-feeding.
  2. Subjects who are actively using injection drugs or other substance abuse (such as extensive alcohol or narcotic use) which is considered by the investigator to be a significant impairment to health and to protocol adherence.
  3. Any medical condition(s) which, in the opinion of the investigator, would interfere with the subject's ability to participate in or adhere to the requirements of this protocol.
  4. History of any illness or drug allergy which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir/ritonavir to the subject.

  5. Active use of any of the following:

    • Investigational HIV-1 vaccines.
    • Any new investigational antiretroviral agent that was not approved for use in the patients prior tipranavir trial.
    • Medications excluded during the trial period (see Section 4.2).
    • Herbal medications (e.g., St. John's Wort).

  6. Active HIV-related or non HIV-related illness that may be negatively affected by use of tipranavir/ritonavir as determined by the investigator.

    If a subject must temporarily discontinue tipranavir/ritonavir at the recommendation of the investigator (at the completion of the previous tipranavir trial), then the subject may enroll in 1182.17 once the clinical illness has resolved, and after approval from the Boehringer Ingelheim Clinical Monitor or Local Clinical Monitor.

  7. Clinically significant liver disease in the 90 days prior to baseline visit, regardless of baseline AST and/or ALT values.
  8. Hypersensitivity to tipranavir or ritonavir.
  9. Voluntary discontinuation of antiretroviral therapy (including tipranavir/ritonavir) for more than seven days from completion of previous tipranavir trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1
Patients With Varying Degrees of Tipranavir Treatment Experience
Drug: Tipranavir
Experimental: Group 2
Highly Tipranavir Treatment Experienced Patients
Drug: Tipranavir
Experimental: Group 3
Tipranavir Treatment Naive Patients
Drug: Tipranavir

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Haemoglobin
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Platelets
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin Time
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Sodium
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Potassium
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Calcium
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Phosphate
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon Dioxide
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline Phosphatase
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Amylase
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine Phosphokinase
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Lipase
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Glucose
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, Total
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatinine
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, Total
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Triglycerides
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric Acid
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Albumin
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)
Number of Patients With Adverse Events Leading to Death
Time Frame: End of Trial (>288 weeks)
NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.
End of Trial (>288 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) Viral Load - Last Observation Carried Forward (LOCF)
Time Frame: Baseline to 192-240 week time interval
Change from baseline in Human Immunodeficiency Virus-Ribonucleic Acid (HIV-RNA) viral load with last observation carried forward (LOCF)
Baseline to 192-240 week time interval
Change From Baseline in CD4 Cell Count (LOCF)
Time Frame: Baseline to 192-240 week time interval
Change from baseline in CD4 cell count with last observation carried forward(LOCF).
Baseline to 192-240 week time interval

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2001

Primary Completion (Actual)

May 1, 2008

Study Registration Dates

First Submitted

September 5, 2005

First Submitted That Met QC Criteria

September 5, 2005

First Posted (Estimate)

September 7, 2005

Study Record Updates

Last Update Posted (Estimate)

March 6, 2014

Last Update Submitted That Met QC Criteria

January 31, 2014

Last Verified

January 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1182.17

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on Tipranavir

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe